+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-ß, CXCR4, CSF-1R, CD47-SIRPa, adenosine pathway & STING 2018

  • PDF Icon


  • 204 Pages
  • July 2018
  • Region: Global
  • La Merie Publishing
  • ID: 4600514
This Competitive Intelligence report analyzes the competitive field of modulators of the tumor microenvironment via IDO & TDO, TGF-beta/R, CXCR4, novel chemokines, CSF-1R, CD47-SIRPalpha, adenosine pathway incl. CD73/CD39 and STING as of July 2018 in a tabulated format with structured listings of industry-relevant data. The report describes the lead indications of each unique molecule in the most advanced R&D stage.

The mainly selective, but also bispecific new molecular entities modulate the tumor microenvironment by targeting:

  • IDO (Indoleamine 2,3-dioxygenase
  • TDO (Tryptophan 2,3 dioxygenase)
  • TGF-ß/R (Transforming Growth Factor beta/Receptor)
  • CXCR4 (Chemokine Receptor Type 4)
  • Novel Chemokines (e.g. CCR2; CCR4, CXCL2, CXCR2, IL-8)
  • CSF-1R (Colony Stimulating Factor-1 Receptor)
  • CD47 – SIRPa (Signal Regulatory Protein Alpha)
  • Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
  • STING (STimulator of INterferon Genes) Receptor
  • Others (e.g. arginase

At least 77 new molecular entities (NMEs) modulating the tumor microenvironment are in clinical development as monotherapy or in combination with checkpoint modulators or other active principles. At least 26 further NMEs are undergoing IND-enabling studies and numerous preclinical approaches are under evaluation.

The report includes a compilation of currently active projects in research and development of new molecular entities modulating the tumor microenvironment by targeting IDO & TDO, TGF-beta/R, CXCR4, novel chemokines, CSF-1R, CD47-SIRPalpha, adenosine pathway incl. CD73/CD39 and STING. In addition, the report lists company-specific R&D pipelines of modulators of the tumor microenvironment.

Competitor projects are listed in a tabular format providing information on:

  • Drug Codes
  • Target/Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage
  • Additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table of Contents

1. Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018
1.1 IDO & TDO Inhibitors

  • First-Generation Selective IDO-1 Inhibitors
  • Novel Selective IDO-1 Inhibitors
  • Dual IDO/TDO Inhibitors
  • Selective TDO Inhibitors
  • Other Approaches for IDO or TDO Inhibition

1.2 TGF-beta Inhibitors

  • Indirect TGF-beta Inhibition
  • Selective TGF-beta1 Inhibitors
  • Selective TGF-beta2 Inhibitors
  • Dual or Triple TGF-beta Inhibitors
  • Bispecific TGF-beta Inhibition

1.3 CXCR4 Antagonists & CXCL2/SDF-1 Inhibitors

  • CXCR4 Antagonists
  • CXCL12 / SDF-1 Inhibitors

1.4 Novel Chemokine Inhibitors & Chemokine Receptor Antagonists

  • Interleukin-8/CXCL8 Inhibitors & CXCR2/CXCR1 Antagonists
  • Other Interleukin Inhibitors
  • CCR2/CCR5 Antagonists
  • CCR4 Antagonists

1.5 CSF-1R Antagonists & CSF-1 Inhibitors

  • Multi-Specific CSF-1R Tyrosine Kinase Inhibitors
  • Selective CSF-1R Antagonists and CSF-1 Inhibitors

1.6 CD47 Antagonists & SIRPalpha Inhibitors

  • CD47 Antagonists
  • SIRPα Inhibitors
  • Bispecific CD47 Antagonists

1.7 Adenosine Pathway Modulation

  • Selective Adenosine A2A Receptor Antagonists
  • Selective Adenosine A2B Receptor Antagonists
  • Dual Adenosine A2 Receptor Antagonists
  • CD73 Ectoenzyme Inhibitors
  • CD39 Ectoenzyme Inhibitors
  • Other Approaches

1.8 STING Agonists

2. Corporate Tumor Microenvironment Modulator R&D Pipelines